Picture a weekly injection, almost painless, that changes a person's entire relationship with food. The phenomenon came out of the United States, carried by celebrities and social media, and it is now crossing the Atlantic. Behind it lies a groundswell that will redraw certain consumption behaviors, sector by sector.

A Molecule That Goes from Diabetes to Cultural Phenomenon

GLP-1 drugs, or glucagon-like peptide-1 agonists, are a class of medications that mimic a hormone naturally released by the gut after a meal. They stimulate insulin secretion, slow gastric emptying, and send a satiety signal to the brain, which reduces appetite. Marketed as Ozempic, Wegovy, or Mounjaro, they were first designed for type 2 diabetes before revealing a spectacular side effect on weight loss.

It is this second use that tipped these treatments from the medical realm into a cultural phenomenon. According to Google Analytics, searches for Ozempic have surged 436% since the start of the decade. In the United States, adoption has exploded: in just over a year, the share of American adults taking this kind of medication more than doubled to reach 12.4%, while the obesity rate fell from nearly 40% in 2022 to 37% in 2025.

Europe is following, at its own regulatory pace. Since June 15, 2026, France has become the first European Union country to durably fold Wegovy and Mounjaro into standard reimbursement, at a rate of 65%. In Belgium, the movement remains more cautious and reveals a telling paradox. With two to two and a half million Belgians affected by obesity, blanket reimbursement would be financially unsustainable for the social security system. Authorities are therefore tightening access: since February 1, 2026, prior authorization from the health insurance fund's medical advisor has become mandatory to obtain reimbursement for Ozempic, Rybelsus, Trulicity, Victoza, and Xultophy, even for a type 2 diabetic patient. The reason for this lockdown speaks volumes about the scale of demand: between 2023 and 2024, the number of reimbursed semaglutide doses nearly doubled, climbing from 5.8 to 9.2 million, and semaglutide rose into the top five most expensive medications reimbursed at the pharmacy.

The strategic signal is clear. Even when a state slows reimbursed access, the pressure of usage keeps climbing.

Meanwhile, certain manufacturers are advancing their pawns by working around the strict rules that govern drug advertising in Europe. The Truth About Weight platform, created by manufacturer Novo Nordisk (Wegovy) and amplified through heavy advertising across every digital platform, sells nothing directly, yet it raises awareness about excess weight and gradually ties a new use case and a brand to the cause.

The Shockwave Runs Through Entire Sectors

The triggering mechanism is simple: these medications cut off food noise, that little voice that drives snacking and cravings. Adults who take GLP-1 drugs consume on average 21% fewer calories and spend nearly a third less on groceries. That individual change, multiplied by millions of people, becomes an economic groundswell. Here are the sectors that will have to reckon with this new consumer.

Food manufacturing and large retail. This is the epicenter of the quake. JPMorgan estimates that the growing use of these medications could wipe out 30 to 55 billion dollars in annual sales for the food and beverage industry as soon as 2030. The impact is not uniform: ultra-processed, calorie-dense foods, the ones tied to cravings, take the steepest declines, with salty snacks dropping around 10% and comparable falls across sweets, pastries, and cookies. Conversely, yogurt rises the most, followed by fresh fruit, nutrition bars, and meat-based snacks. The basket shrinks and reconfigures toward protein and nutritional density. Players specialized in weight loss such as Weight Watchers are already communicating about programs designed to support users of these new treatments.

Restaurants. The blow is more diffuse but real. In the six months following the start of treatment, users reduce their restaurant spending by 8.6%. An analysis by Cornell University shows that GLP-1 adoption cuts spending at fast-food chains and coffee shops by roughly 8%. The most exposed names are those that live on impulse and snacking. As some analysts point out, a restaurant never sells only food: it sells convenience, or an experience, two levers that can cushion the blow for those who know how to activate them. Building adapted menus through smaller portions is also an option worth considering in order to serve consumers who feel full sooner.

Apparel and fashion retail. When bodies change fast, wardrobes follow. About 80% of GLP-1 users anticipate needing new clothes tied to their change in size, and 55% have already bought some. This creates a tailwind for mainstream fashion and a fresh difficulty for plus-size ready-to-wear. Secondhand, for its part, is thriving: spending on consignment and thrift stores among GLP-1 users has jumped 80%, and resale outlets are seeing a flood of larger-size donations. Brands face a size volatility that complicates production, inventory allocation, and the very design of garments.

Beverages and alcohol. The satiety effect spills over into festive consumption. People on GLP-1 drugs consume 65% fewer sugary drinks and 62% less alcohol. For brewers, spirits producers, and soda brands, this is a signal to fold into any five- or ten-year projection.

Fitness, beauty, and aesthetics. The side effects of these treatments create their own markets. Hair loss, loss of muscle mass, and nausea have driven up sales of supplements, hair-growth products, and electrolytes among users. Rapid muscle loss pushes toward weight training and protein intake, while the hollowing face (the famous "Ozempic face") fuels demand for skincare and aesthetic procedures.

Beyond the Numbers: The Return of an Imaginary

Reducing GLP-1 drugs to a mechanics of shopping baskets would mean missing the point. What is being replayed is a collective imaginary of the body. The body positive movement fell from favor the moment thinness became chemically accessible, and slim silhouettes dominate once again. The return of 2000s codes, from low-rise jeans to very thin models on the runways, accompanies this shift. For brands that had built part of their discourse on body diversity, a positioning dilemma is looming, caught between loyalty to stated values and the temptation to follow the current.

This point deserves the attention of every leader, because it illustrates a dynamic we observe often: a signal that seems to belong to the medical or cultural realm ends up redefining the expectations of an entire market. Eating behaviors change, but so do sports habits, the relationship to pleasure, and the social rituals around meals and drinks. Tomorrow's consumer will eat less, choose better, buy differently, and judge brands against new criteria.

Tomorrow's World Is Being Prepared Today

One nuance is essential, though: these treatments accelerate a movement that is already underway, that of a more deliberate consumption, more attentive to health and quality. From now on, GLP-1 drugs are creating a group of consumers whose biology pushes them durably toward fewer calories and more targeted choices.

For European companies, the window is still open. Adoption here is progressing more slowly than in the United States, held back by reimbursement trade-offs and health caution. That leaves precious time to observe the American laboratory, anticipate the reconfigurations, and rethink value propositions before the wave fully breaks. The winners will not be those who resisted best, but those who read the signal early and turned an apparent threat into fertile ground for innovation.

At Hypevision, this is exactly the work we carry out alongside companies and organizations. We decode the still-quiet markers, whether behavioral, sociological, or technological, to help our clients understand how their markets will transform and to build a growth strategy aligned with the world that is coming. Because a signal that looks marginal today often traces the norm of tomorrow, and anticipating is always better than enduring.

💬 Want to understand how these shifts will reach your sector and build a strategy ready for your consumers of tomorrow? We would be glad to talk it through.

Sources

• Cornell University / Journal of Marketing Research, How GLP-1 Medication Adoption is Changing Consumer Food Demand, 2025
• CNBC, GLP-1 drugs are changing how Americans eat, 2026
• Washington Post, Ozempic is changing the consumer economy, 2025
• McGill Journal of Economics, The "Ozempic Effect" on Food Companies, 2026
• Circana / TheStreet, GLP-1 weight loss disrupting fashion retail demand, 2026
• UC Davis Innovation Institute for Food and Health, The Impact of GLP-1 Drugs on the Food Industry, 2025
• The Irish Times, Body positivity fell from favour as soon as Ozempic brought thinness back, 2025
• Euronews, France becomes the first country in Europe to reimburse anti-obesity medications, 2026
• INAMI, Antidiabetic medications: prior authorization for GLP-1 reimbursement, 2026
• Moustique, The troubling rise in semaglutide spending in Belgium, 2026